Index
RUT
Market Cap
454.61M
Enterprise Value
431.38M
Income
-32.94M
Sales
325.38M
Book/sh
3.86
Cash/sh
0.81
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
632
IPO
May 27, 2004
P/E
-
Forward P/E
-
PEG
-
P/S
1.40
P/B
2.80
P/C
13.38
P/FCF
-
EV/EBITDA
149.78
EV/Sales
1.33
Quick Ratio
1.48
Current Ratio
2.40
Debt/Eq
0.07
LT Debt/Eq
0.05
Option/Short
Yes / Yes
EPS (ttm)
-0.79
EPS next Y
-0.11
EPS next Q
-0.07
EPS this Y
-81.36%
EPS next Y
58.34%
EPS next 5Y
-
EPS past 3/5Y
12.67% -1.46%
Sales past 3/5Y
-1.86% 1.93%
EPS Y/Y TTM
-0.88%
Sales Y/Y TTM
8.20%
EPS Q/Q
36.22%
Sales Q/Q
6.87%
Insider Own
11.52%
Insider Trans
-1.00%
Inst Own
89.15%
Inst Trans
-4.76%
ROA
-12.98%
ROE
-19.21%
ROIC
-19.05%
Gross Margin
52.34%
Oper. Margin
-6.01%
Profit Margin
-10.12%
SMA20
-8.70%
SMA50
-16.96%
SMA200
-14.04%
Trades
Shs Outstand
42.42M
Shs Float
37.21M
52W High
16.29 -33.64%
52W Low
9.39 15.12%
Volatility
4.29% 4.14%
ATR (14)
0.54
RSI (14)
32.61
Beta
0.32
Rel Volume
0.67
Avg Volume
639.28K
Volume
430,800
Perf Week
-8.93%
Perf Month
-10.07%
Perf Quarter
-31.45%
Perf Half Y
-9.31%
Perf YTD
-15.81%
Perf Year
-5.26%
Perf 3Y
57.35%
Perf 5Y
-62.10%
Perf 10Y
-35.73%
Prev Close
10.76
Price
10.81
Change %
0.46%
Analysts 11 incl. previous ratings
Rating Distribution 6 Buy · 5 Hold · 0 Sell
Date Action Analyst Rating Change Price Target Change Implied Upside Jul 16, 2025 Initiated L Lake Street
Buy $24 +122.0% Apr 05, 2024 Upgrade O Oppenheimer
Perform → Outperform $12 +11.0% Sep 25, 2023 Initiated H H.C. Wainwright
Buy $19 +75.8% Apr 17, 2023 Downgrade R Raymond James
Strong Buy → Outperform $14 → $13 +20.3% Oct 15, 2021 Upgrade C Canaccord Genuity
Hold → Buy $28 → $37 +242.3% Aug 20, 2021 Initiated O Oppenheimer
Perform Nov 25, 2020 Upgrade R Raymond James
Mkt Perform → Strong Buy $18 +66.5% Apr 08, 2020 Downgrade K KeyBanc Capital Markets
Overweight → Sector Weight Apr 01, 2019 Upgrade K KeyBanc Capital Markets
Sector Weight → Overweight Apr 03, 2018 Upgrade R Raymond James
Mkt Perform → Outperform Jan 05, 2018 Downgrade C Craig Hallum
Buy → Hold Apr 07, 2017 Reiterated C Cantor Fitzgerald
Overweight $20 → $21 +94.3% Mar 30, 2017 Downgrade K KeyBanc Capital Mkts
Overweight → Sector Weight Feb 08, 2017 Initiated B Barclays
Equal Weight $17 +57.3% Nov 04, 2016 Initiated C Cantor Fitzgerald
Buy Apr 08, 2016 Resumed P Piper Jaffray
Neutral Jan 08, 2016 Reiterated C Canaccord Genuity
Buy $17.50 → $14.50 +34.1% Nov 10, 2015 Downgrade R Raymond James
Outperform → Mkt Perform Jul 24, 2015 Initiated K KeyBanc Capital Mkts
Overweight Jun 19, 2014 Upgrade C Canaccord Genuity
Hold → Buy $16.25 → $20 +85.0%
Show Previous Ratings
Nov-06-26 05:00PM
Oct-29-26 08:00AM
Oct-21-26 08:30AM
Oct-14-26 07:00AM
Oct-08-26 08:19AM
06:51AM
Loading…
06:51AM
06:13AM
06:02AM
06:00AM
05:03AM
03:35AM
Oct-02-26 06:00AM
Sep-28-26 04:30PM
Jul-28-26 08:30AM
Jul-14-26 03:00PM
06:49AM
Loading…
06:49AM
06:18AM
06:00AM
Jun-30-26 08:00AM
Jun-17-26 08:30AM
May-28-26 01:25PM
May-27-26 08:30AM
May-13-26 09:00AM
Apr-10-26 08:11PM
Apr-02-26 03:00PM
06:11AM
06:00AM
Mar-31-26 08:00AM
Mar-19-26 08:00AM
Mar-05-26 01:00PM
09:31AM
Loading…
09:31AM
Mar-02-26 08:25AM
Feb-27-26 12:43PM
09:40AM
Feb-25-26 11:50AM
Feb-23-26 04:30PM
12:42PM
Feb-19-26 08:30AM
Feb-16-26 08:54AM
Feb-13-26 01:11PM
12:35PM
Feb-06-26 09:55AM
Feb-05-26 11:30AM
08:00AM
Feb-04-26 12:51PM
Feb-03-26 08:00AM
Jan-30-26 09:55AM
Jan-29-26 12:47PM
Jan-14-26 07:04PM
10:13AM
Jan-13-26 01:40PM
Jan-12-26 09:35AM
Jan-07-26 12:11PM
Jan-06-26 02:00PM
11:24AM
09:27AM
(Associated Press Finance)
09:03AM
06:00AM
Dec-24-25 12:29PM
Dec-23-25 08:00AM
Dec-22-25 08:00AM
Nov-21-25 10:50AM
Oct-27-25 04:30PM
Oct-26-25 06:16AM
Oct-13-25 08:30AM
Oct-03-25 12:47PM
08:21AM
Oct-02-25 03:01PM
12:28PM
07:10AM
06:08AM
(Associated Press Finance)
06:00AM
Oct-01-25 09:15AM
Sep-22-25 12:27PM
Sep-18-25 08:00AM
Sep-09-25 06:45PM
Aug-28-25 11:30AM
Aug-21-25 01:30PM
Aug-14-25 04:04AM
Aug-06-25 04:30PM
Jul-28-25 08:30AM
Jul-25-25 11:13AM
Jul-23-25 08:30AM
Jul-18-25 07:02AM
Jul-16-25 12:35PM
03:03AM
Jul-15-25 04:42PM
07:40AM
06:44AM
(Associated Press Finance)
06:30AM
Jul-14-25 09:18AM
Jul-07-25 08:00AM
Jun-26-25 10:55AM
08:23AM
Jun-24-25 10:43AM
Jun-23-25 08:00AM
Jun-20-25 11:40AM
11:36AM
Jun-18-25 09:55AM
Show Previous News
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Trowbridge Stephen A EVP and CFO Oct 29 '26 Sale 12.27 23,615 289,756 280,461 Oct 30 04:15 PM Trowbridge Stephen A EVP and CFO Oct 28 '26 Sale 12.17 1,720 20,932 304,076 Oct 30 04:15 PM STEPHEN TROWBRIDGE Officer Oct 29 '26 Proposed Sale 12.27 23,615 289,722 Oct 29 04:02 PM Nighan Warren JR SVP Quality and Regulatory Jul 30 '26 Sale 14.72 23,370 344,006 64,745 Jul 31 04:45 PM WARREN NIGHAN Officer Jul 30 '26 Proposed Sale 14.72 23,370 344,004 Jul 30 06:02 PM Piccinini Laura SVP International Jul 22 '26 Option Exercise 0.00 8,047 0 86,435 Jul 24 06:10 PM Nighan Warren JR SVP Quality and Regulatory Jul 22 '26 Option Exercise 0.00 5,694 0 89,786 Jul 24 06:10 PM Trowbridge Stephen A EVP and CFO Jul 22 '26 Option Exercise 0.00 16,296 0 314,115 Jul 24 06:10 PM Clemmer James C President and CEO Jul 22 '26 Option Exercise 0.00 52,358 0 889,176 Jul 24 06:10 PM Campbell Chad Thomas SVP/GM, Vascular Access Jul 22 '26 Option Exercise 0.00 6,466 0 111,006 Jul 24 06:10 PM
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The firm offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The Med Tech segment consists of technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment focuses on core, venous, ports, and other oncology products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
Executive VP & CFO Mr. Stephen A. Trowbridge
Senior VP Mr. Lawrence T. Weiss
Senior Vice President of Regulatory Affairs Mr. Warren G. Nighan
Senior VP and GM of Cardiovascular & International Ms. Laura Piccinini
President Mr. Eric Honroth